Individual and institutional investors, as well as advisors and analysts are invited to attend a real-time, interactive presentation on VirtualInvestorConferences.com
TORONTO, June 22, 2020 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, today announced that Alvaro Torres, Khiron CEO and director, and Chris Naprawa, Khiron Board Chair and director will present live at VirtualInvestorConferences.com on June 24th.
DATE: Wednesday, June 24th
TIME: 10:30am ET
PARTICIPANTS: Alvaro Torres, Khiron CEO and director, and Chris Naprawa, Khiron Board Chair and director
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com.
Recent Company Highlights
- Achieved first sales in Colombia of low-THC medical cannabis and began first high-THC medical cannabis sales in Colombia. Only company authorized to sell medical cannabis in Colombia and export high-THC cannabis from Colombia
- Received first medical cannabis prescriptions for UK patients participating in Project Twenty21
- Signed exclusive agreement with Medlive, a distributor serving 3,000 clinics and hospitals in Brazil
- Signed exclusive agreement with Farmacia Universal to manufacture and distribute Khiron-branded medical cannabis products in Lima, Peru´s largest city with 8.6 million residents
- Launched teleconsultation service in Colombia giving patients access to health services and doctors trained to prescribe medical cannabis
- Entered agreement with Tecnologico de Monterrey, a leading Latin American university in Mexico bringing Khiron´s online education program to 1,500 physicians and healthcare practitioners
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.
A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group's suite of investor relations services specifically designed for more efficient Investor Access. Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.
About Khiron Life Sciences Corp.
Khiron is a vertically integrated global medical and CPG cannabis leader with core operations in Latin America, and operational activity in Europe and North America. Khiron is the first company licensed in Colombia for the cultivation, production, domestic distribution, and international export of both low and high THC medical cannabis products from Colombia to the UK, Peru and Uruguay/Brazil.
Leveraging its first-mover advantage, and patient oriented approach, Khiron combines global scientific expertise, product innovation, agricultural infrastructure, wholly-owned medical clinics, and online doctor education programs to drive prescription and brand loyalty to address priority medical conditions. Its Wellbeing unit launched the first branded CBD skincare brand in Colombia, with Kuida now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a Board of Directors that includes Board Chair and capital markets authority Chris Naprawa, Audit Committee Chair and Founder of Women Get On Board Deborah Rosati, and Vicente Fox, the 55th President of Mexico.
Visit Khiron online at www.khiron.ca, investors.khiron.ca and on Instagram @khironlife
This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.